S1PR1 and multiple sclerosis: Ceralifimod (ONO-4641, S1P1/5 modulator) reduced the number of new/enlarging T2 lesions in multiple sclerosis patients switching from placebo to active treatment in the extension study (Drug Research and EvaluAtion in Multiple Sclerosis, DreaMS), while efficacy was sustained for patients on continuous active treatment [98].